Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
Xiangrui Meng, Tao Wu, Yonggui Hong, Qingxia Fan, Zhonghai Ren, Yanzhen Guo, Xiuli Yang, Pei Shi, Jiamei Yang, Xianzhe Yin, Zhiquan Luo, Jin Xia, Yue Zhou, Mengli Xu, Enjie Liu, Guozhong Jiang, Shenglei Li, Feng Zhao, Chi Ma, Chuanxiang Ma, Zhiguo Hou, Jing Li, Junsheng Wang, Feng Wang
Topics & Concepts
ApatinibMedicineInternal medicineAdverse effectClinical endpointPhases of clinical researchOncologyResponse Evaluation Criteria in Solid TumorsSorafenibSurgeryChemotherapyClinical trialGastroenterologyHepatocellular carcinomaEsophageal Cancer Research and TreatmentCancer Immunotherapy and BiomarkersColorectal and Anal Carcinomas